Ayyoub Kihel

Dr. Ayyoub Kihel

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Cytokine
Verified
Journal Article
Closed access
Ayyoub KihelAyyoub Kihel
Ayyoub Kihel
IHIkram Hammi
Ikram Hammi
DDDounia Darif
Dounia Darif
MLMeryem Lemrani
Meryem Lemrani
MRMyriam Riyad
Myriam Riyad
KAKhadija AKARID
Khadija AKARID

26 December 2022 in Experimental Parasitology
Verified
Journal Article
Closed access
DDDounia DARIF
Dounia DARIF
IIImane NAIT IRAHAL
Imane NAIT IRAHAL
IHIkram Hammi
Ikram Hammi
Ayyoub KihelAyyoub Kihel
Ayyoub Kihel
MKMohamed Reda Kachmar
Mohamed Reda Kachmar
KAKhadija AKARID
Khadija AKARID

3 December 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
AAAicha Assouab
Aicha Assouab
Ayyoub KihelAyyoub Kihel
Ayyoub Kihel
MRMyriam Rouahi
Myriam Rouahi
MLMathilde Larribau
Mathilde Larribau
ZKZoubida Karim
Zoubida Karim
KAKhadija AKARID
Khadija AKARID
Leishmaniasis is a vector-borne parasitic infection induced by protozoa of the genus Leishmania. The disease spectrum ranges from skin lesions to visceral leishmaniasis, which is fatal if untreated. The cutaneous leishmaniasis is characterized by a clinical polymorphism of lesions with a broad range of severity ranging from a self-limited lesion to multiple disfiguring lesions stigmatizing the patient for life. Although iron is required for several process of Leishmania infection including survival, growth and virulence, the number of studies on host iron metabolism during this infection remains limited. Iron homeostasis in the body is finely regulated by hepcidin, a hyposideremic peptide highly expressed in the liver. In infectious contexts, hepcidin plays additionally an antimicrobial role, acting through various mechanisms such as retaining iron in tissues, modulating the immune response, and operating as a defensin against gram-negative bacteria. This review mainly summarizes the most important interconnections between iron metabolism, hepcidin and leishmaniasis. A deeper understanding of iron metabolism in this context could help in developing innovative treatment strategies that target the parasite while simultaneously reinforcing host defenses.

27 February 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
Ayyoub KihelAyyoub Kihel
Ayyoub Kihel
HFHajar El Filaly
Hajar El Filaly
DDDounia DARIF
Dounia DARIF
AAAicha Assouab
Aicha Assouab
MRMyriam Riyad
Myriam Riyad
KAKhadija AKARID
Khadija AKARID
Leishmaniasis, caused by the Leishmania parasite, is a neglected public health issue. Leishmania mainly infects macrophages, where metabolic reprogramming shapes their plasticity (M1/M2), affecting the host’s resistance or susceptibility to infection. The development of this infection is influenced by immune responses, with an excessive anti-inflammatory reaction linked to negative outcomes through the modulation of various mediators. Itaconate, produced by the Acod1 gene, is recognized for its anti-inflammatory effects, but its function in leishmaniasis is not well understood. This study aimed to investigate the potential role of itaconate in leishmaniasis. Using transcriptomic data from L. major-infected BMDMs, we assessed the expression dynamics of Il1b and Acod1 and performed pathway enrichment analysis to determine the profile of genes co-expressed with Acod1. Early Acod1 upregulation followed by later Il1b downregulation was noted, indicating a shift towards an anti-inflammatory response. Among the genes co-expressed with Acod1, Ldlr, Hadh, and Src are closely associated with lipid metabolism and the polarization of macrophages towards the M2 phenotype, thereby creating a favorable environment for the survival of Leishmania. Overall, these findings suggest that Acod1 and its co-expressed genes may affect the outcome of Leishmania infection by modulating host metabolism. Accordingly, targeting itaconate-associated pathways could provide a novel therapeutic strategy for leishmaniasis.

5 November 2021
Verified
Journal Article
Open access
SCSoumiya Chiheb
Soumiya Chiheb
ZSZineb Tazi Saoud
Zineb Tazi Saoud
ISImane EL Idrissi Saik
Imane EL Idrissi Saik
DDDounia DARIF
Dounia DARIF
FHFouzia Hali
Fouzia Hali
MRMyriam Riyad
Myriam Riyad
Post-kala-azar dermal Leishmaniasis (PKDL) is a rare skin syndrome observed after treatment of visceral Leishmaniasis (VL) with pentavalent antimonial organic salts, never described in Morocco before. Here we report a case in an immunocompetent adult. A 36-year-old-man from Tata in southern Morocco, with a history of visceral Leishmaniasis 2 years before and treated with meglumine antimoniate and amphotericin B with good clinical course, was hospitalized in dermatology for an erythematous papulo-nodular closet of the face. Six months ago, he presented oral mucosa involvement, then 3 months later, cutaneous lesions appeared on the face. The dermatological examination revealed a papulo-nodular erythematous closet extending to the nose and both cheeks, crusty and lupoid lesions on the forehead, around the eyes and chin, associated with an ulcerative and painless lesion on the heeL. The examination of the oral mucosa revealed an ulceration of the posterior third of the tongue and a papillomatous aspect of the soft palate. The skin biopsy and smear found some amastigote forms of Leishmania bodies. ITS1 PCR was positive (genus Leishmania). The HIV serology was negative. The diagnosis of PKDL was then evoked. The patient received intra-muscular injections of meglumine antimoniate with good progress. To our knowledge, this is the first case of generalised leishmaniasis suggesting PKDL reported in a Moroccan immunocompetent adult.